Cipher Pharmaceuticals Inc. (CPHRF)

Market Cap	337.76M +63.8%
Revenue (ttm)	50.45M +51.2%
Net Income	27.33M +136.7%
EPS	1.05 +128.3%
Shares Out	n/a
PE Ratio	12.36
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	3,665
Open	13.20
Previous Close	13.20
Day's Range	13.20 - 13.37
52-Week Range	8.54 - 14.17
Beta	0.52
RSI	52.89
Earnings Date	May 7, 2026

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the manage...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: CPHRF

Financial Performance

In 2025, Cipher Pharmaceuticals's revenue was $50.45 million, an increase of 51.22% compared to the previous year's $33.36 million. Earnings were $27.33 million, an increase of 136.72%.